文献速递免疫规划传染病防控与疫情报告卫生政策与健康促进

研讨会报告:针对HIV疫苗的核酸递送装置:研讨会会议记录,美国国家过敏与传染病研究所,马里兰州贝塞斯达,2015年5月21日

Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015.
PubMed 文献 · Vaccine · 2017-11-22

2015年5月21日,美国国家过敏与传染病研究所(NIAID)召开研讨会,审查用于将核酸(NA)(如DNA、RNA等)作为抗原递送至动物模型和人类靶组织的递送装置现状与未来技术。会议聚焦于预防和治疗HIV感染及艾滋病(AIDS)的当前和未来应用,与会者介绍了使用多种替代递送装置的NA疫苗代表性临床试验结果和经验,以及在动物模型和实验台上研究的更广泛方法。

要点

  • 研讨会总结了核酸疫苗递送装置在HIV预防和治疗中的应用前景。
  • 讨论了多种靶组织递送、装置技术、抗原佐剂载体及免疫应答。
  • 会议内容涵盖临床试验经验与动物模型研究,并在线存档。

核心结论

  • 研讨会审查了核酸疫苗递送装置的现状与未来技术,重点关注HIV感染和AIDS的预防与治疗。

研究设计与样本

  • 美国国家过敏与传染病研究所(NIAID)于2015年5月21日召开研讨会,参会者展示代表性临床试验结果及动物模型和实验台研究。

主要发现

  • 参会者介绍了针对口腔、皮肤/皮内、鼻腔、上呼吸道和下呼吸道及肌肉组织的递送。
  • 讨论了喷射注射、实心、空心和溶解性微针、贴片、离子电渗、电穿孔、热微孔、鼻腔喷雾器、气溶胶吸入、超声角质层消融、化学和机械磨损及动力学/弹道递送等装置和技术。
  • 涉及DNA、信使RNA、合成质粒、趋化因子、湿和干气溶胶、花粉粒和微粒载体等抗原、佐剂和载体。
  • 报告了许多靶组织、技术和载体观察到的体液、细胞和细胞因子免疫应答的临床经验。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

On May 21st, 2015, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop on delivery devices for nucleic acid (NA) as vaccines in order to review the landscape of past and future technologies for administering NA (e.g., DNA, RNA, etc.) as antigen into target tissues of animal models and humans. Its focus was on current and future applications for preventing and treating human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) disease, among other infectious-disease priorities. Meeting participants presented the results and experience of representative clinical trials of NA vaccines using a variety of alternative delivery devices, as well as a broader group of methods studied in animal models and at bench top, to improve upon the performance and/or avoid the drawbacks of conventional needle-syringe (N-S) delivery. The subjects described and discussed included (1) delivery targeted into oral, cutaneous/intradermal, nasal, upper and lower respiratory, and intramuscular tissues; (2) devices and techniques for jet injection, solid, hollow, and dissolving microneedles, patches for topical passive diffusion or iontophoresis, electroporation, thermal microporation, nasal sprayers, aerosol upper-respiratory and pulmonary inhalation, stratum-corneum ablation by ultrasound, chemicals, and mechanical abrasion, and kinetic/ballistic delivery; (3) antigens, adjuvants, and carriers such as DNA, messenger RNA, synthesized plasmids, chemokines, wet and dry aerosols, and pollen-grain and microparticle vectors; and (4) the clinical experience and humoral, cellular, and cytokine immune responses observed for many of these target tissues, technologies, constructs, and carriers. This report summarizes the presentations and discussions from the workshop (https://web.archive.org/web/20160228112310/https://www.blsmeetings.net/NucleicAcidDeliveryDevices/), which was webcast live in its entirety and archived online (http://videocast.nih.gov/summary.asp?live=16059).

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Weniger BG, Anglin IE, Tong T, et al. Workshop report: Nucleic acid delivery devices for HIV vaccines: Workshop proceedings, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland, USA, May 21, 2015. Vaccine. 2017. PMID: 29174315. doi:10.1016/j.vaccine.2017.10.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。